{Reference Type}: Journal Article
{Title}: Risk assessment for biopharmaceutical single-use manufacturing: A case study of upstream continuous processing.
{Author}: Ito T;Wang H;Hwang SH;Wang B;Wang L;G S;
{Journal}: Biologicals
{Volume}: 84
{Issue}: 0
{Year}: 2023 Nov 2
{Factor}: 1.76
{DOI}: 10.1016/j.biologicals.2023.101713
{Abstract}: In the current transition to intensified upstream processing, the risks of adopting traditional single-use systems for high-titer, long-duration perfusion cultures, have thus far not been considered. This case study uses the Failure Modes and Effects Analysis (FMEA) method to evaluate the risks associated with implementing upstream single-use technology. The simulated model process was used to compare the risk level of single-use technology for a traditional fed-batch cell culture with that for perfusion culture, under the same annual protein production conditions. To provide a reasonable source of potential risk for FMEA, all single-use upstream operations for both fed-batch and perfusion processes were investigated using an analytical method developed to quantify the impact of process parameters and operating conditions on single-use system specifications and to ensure objectivity. Many of the risks and their levels, were similar in long-duration perfusion cultures and fed-batch cultures. However, differences were observed for high-risk components such as daily sampling and installation. The result of this analysis indicates that the reasons for risk are different for fed-batch cultures and perfusion cultures such as larger bioreactors in fed-batch and longer runs in perfusion, respectively. This risk assessment method could identify additional control measures and be part of a holistic contamination control strategy and help visualize their effectiveness.